

Structure and conserved function of iso-branched sphingoid bases from the nematode *Caenorhabditis elegans*

J. Thomas Hannich^{1,3}, Denia Mellal^{2,3,4}, Suihan Feng^{1,3}, Andreas Zumbuehl^{2,3,*}, Howard Riezman^{1,3,*}

¹ Department of Biochemistry, University of Geneva, CH-1205 Geneva, Switzerland,

² Department of Chemistry, University of Fribourg, CH-1700 Fribourg, Switzerland,

³ National Center of Competence in Research (NCCR) “Chemical Biology”,


⁴ Current address: MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, United Kingdom

* Equal contribution.

Corresponding author: howard.riezman@unige.ch

Supplementary Information on Chemical Synthesis

General scheme:




Experimental Part:

General reagents and materials

12-methyl tridecanol was from Endeavour Speciality Chemicals, all other starting compounds and solvents were purchased from Sigma-Aldrich/Fluka or Acros and were used without further purification. Column chromatographic separations were carried out using 230-400 mesh silica gel. TLC plates were developed with potassium permanganate mixture (1 g of KMnO_4 , 2 g of Na_2CO_3 , 100 mL of H_2O). ^1H , and ^{13}C NMR spectra were recorded (as indicated) on either a Bruker 300 MHz or 400 MHz spectrometer and are reported as chemical shifts (δ) in ppm relative to TMS ($\delta = 0$). Spin multiplicities are reported as a singlet (s) or triplet (t) with coupling constants (J) given in Hz, or multiplet (m). ESI-MS for the characterization of compounds was performed on an ESI API 150EX and are reported as mass-per-charge ratio. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer (ATR, Golden Gate). Optical rotation was measured on a Jasco P-1030 polarimeter. All reactions were performed under an Ar or N_2 atmosphere.

(*S*)-*N*-methoxy-*N*-methyl-1-((*R*)-1-phenylethyl)aziridine-2-carboxamide (**2**)



A literature protocol was followed.¹

Method A : To (2*S*)-2-isopropyl-4-methoxycyclohexyl 1-((*R*)-1-phenylethyl)aziridine-2-carboxylate **1** (1.00 g, 2.89 mmol, 1 equiv.) and Weinreb's amine or *N,O*-dimethylhydroxylamine.HCl (450 mg, 7.4 mmol, 2.5 equiv.) in 10 mL THF was slowly added isopropyl magnesium chloride (4.60 mL, 9.2 mmol, 3.2 equiv., 2.0 M in THF) at 0 °C. The resulting mixture was warmed to rt and after 30 min, it was partitioned between CH_2Cl_2 and H_2O . The water phase was washed with CH_2Cl_2 (3 × 20 mL). The combined organic solvents were dried over MgSO_4 and the solvent was evaporated under reduced pressure. The crude product was purified on a silica gel column (EtOAc/Pentane gradient 1:1 to 1:0) in order to give Weinreb's amide or *N*-(*R*)-(+)- α -methylbenzyl-2-(*S*)-aziridine *N*-Methoxy-*N*-methylcarboxamide **2** as a white powder (298 mg, 44 %).

Method B : To the solid of *N,O*-dimethylhydroxylamine-HCl (880 mg, 9.11 mmol, 3 equiv.) in 10 mL of CH_2Cl_2 was carefully added trimethylaluminium (4.55 mL, 9.11 mmol, 3 equiv., 2.00M) under nitrogen at -10 °C. The solution was stirred for 30 min at rt and then a solution of (2*S*)-2-isopropyl-4-methoxycyclohexyl 1-((*R*)-1-phenylethyl)aziridine-2-carboxylate **1** (1.00 g, 3.04 mmol) in 5.0 mL CH_2Cl_2 was added dropwise at -10 °C. The mixture was stirred for 2 h at rt. Then the reaction was quenched carefully with water and the organic layer was separated. After extraction with CH_2Cl_2 (3 × 20 mL), the combined organic layers were dried, filtered, and concentrated under vacuum. Purification by silica gel flash chromatography (EtOAc/cyclohexane, 75:15 to 50:50 to 100:0) yielded pure *N*-(*R*)-(+)- α -methylbenzyl-2-(*S*)-aziridine *N*-Methoxy-*N*-methylcarboxamide **2** as an oil (321 mg, 45%).


$[\alpha]_D^{22} = + 13.1$ (c 1.00, CHCl_3).²

$R_f = 0.10$ (EtOAc/Pentane 1:0).


^1H NMR (300 MHz, CDCl_3) : $\delta = 7.44 - 7.08$ (m, 5H) , 3.11 (d, $J = 8.3$ Hz, 6H), 2.55 (q, $J = 6.4$ Hz, 2H), 2.40 (d, $J = 3.0$ Hz, 1H), 1.74 (d, $J = 6.4$ Hz, 1H), 1.46 (d, $J = 6.5$ Hz, 3H).

¹ J-W. Kim, Y-W. Kim, Y. Inagaki, Y-A. Hwang, S. Mitsutake, Y-W. Ryu, W. K. Lee, H-J. Ha, C-S. Park, Y. Igarashi, *Bioorganic & Medicinal Chemistry*, **2005**, *13*, 3475-3485.

² This value has been confirmed by personal communication with Ha *et al.* The reported value in *J. Org. Chem.* **2003**, *68*, 7675-7680 stands corrected.



1-bromo-12-methyltridecane (4)




Method A : 12-methyl-1-tridecanol **3** (1.00 g, 4.66 mmol) was dissolved in CH_3CN and bromotrimethylsilane (1.79 g, 11.7 mmol, 2.5 equiv.) was added. The solution was heated to $90\text{ }^\circ\text{C}$ for 5 h. Then 2 mL H_2O were added. The solvents were removed under reduced pressure and the crude material was purified on a silica gel column (hexanes) in order to give 1-bromo-12-methyltridecane as a clear oil (380 mg, 29 %).

Method B : 12-methyl-1-tridecanol **3** (2.00 g, 9.3 mmol) was dissolved in CH_2Cl_2 (25 mL) and PPh_3 (4.40 g, 16.6 mmol, 1.2 equiv.), and pyridine (1.3 mL, 16.6 mmol, 1.2 equiv.) were added. The flask was cooled down to $0\text{ }^\circ\text{C}$ after that bromine Br_2 was added dropwise (0.56 mL, 16.6 mmol, 1.2 equiv.). The solution became orange and the reaction was stirred for 3 h at rt. The solvent was removed under reduced pressure and the orange crude material was filtered on a silica gel column using CH_2Cl_2 to afford to 1-bromo-12-methyltridecane **4** as yellow oil (3.42 g, 88 %).


$R_f = 0.75$ (Hexanes).

$^1\text{H NMR}^3$ (400 MHz, CDCl_3) : $\delta = 3.45$ (t, $J = 6.9$ Hz, 2H), 1.98 – 1.79 (m, 2H), 1.66 – 1.51 (m, 1H), 1.47 (dd, $J = 14.3, 7.0$ Hz, 2H), 1.32 (d, $J = 7.3$ Hz, 14H), 1.20 (dd, $J = 13.3, 6.5$ Hz, 2H), 0.92 (d, $J = 6.6$ Hz, 6H).

³ J. Y. Mun, A. Onorato, F. C. Nichols, M. D. Morton, A. I. Saleh, M. Welzel, M. B. Smith. *Organic & Biomolecular Chemistry*, **2007**, *5*, 3826-3833.



13-methyl-1-((*S*)-1-((*R*)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one (**6**)



1-bromo-12-methyltridecane **4** (413 mg, 1.7 mmol, 1.5 equiv.) was dissolved in 2 mL THF. Mg turnings (40.3 mg, 1.7 mmol, 1.5 equiv.) were added together with a drop of I₂. The reaction was heated in order to initiate the Grignard reaction. The mixture of **5** was slowly added to (*S*)-*N*-methoxy-*N*-methyl-1-((*R*)-1-phenylethyl)aziridine-2-carboxamide **2** (259 mg, 1.1 mmol) in 5 mL THF at -78 °C. The reaction was stirred for 30 min and then the cold-bath was removed. After reaching rt, the mixture was quenched with 5 mL H₂O and extracted with CH₂Cl₂ (3 × 10 mL). The organic phase was dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. The crude material was purified on a silica gel column (EtOAc/Pentane 1:4) and the pure compound **6** was isolated as a clear oil (199 mg, 0.54 mmol, 48 %).

$[\alpha]_D^{24} = -53.9$ (c 1.00, CHCl₃).



$R_f = 0.40$ (EtOAc: Pentane 1:9).

HRMS-ESI (m/z) : [M+H]⁺ calcd for C₂₅H₄₂NO: 372.326; found 372.3259.


IR (Golden Gate) : 2925 (s), 2853 (m), 1702 (m), 1451 (w).

¹H NMR (300 MHz, CDCl₃) : δ = 7.28 – 7.15 (m, 5H), 2.48 (q, *J* = 6.6 Hz, 1H), 2.37 – 2.25 (m, 1H), 2.23 – 2.11 (m, 2H), 2.06 (dd, *J* = 6.7, 3.1 Hz, 1H), 1.73 (d, *J* = 6.8 Hz, 1H), 1.53 – 1.43 (m, 1H), 1.42 – 1.31 (m, 5H), 1.26 – 1.02 (m, 18H), 0.81 (d, *J* = 6.6 Hz, 6H).

^{13}C NMR (101 MHz, CDCl_3) : δ = 208.73, 143.96, 128.48, 127.30, 126.59, 70.05, 44.02, 39.10, 38.65, 35.47, 29.99, 29.76, 29.71, 29.66, 29.50, 29.41, 29.19, 28.01, 27.47, 23.47, 22.72.



(R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol (7)



Method A : To 13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one **6** (150 mg, 404 μmol) in 2 mL dry MeOH at $-78\text{ }^{\circ}\text{C}$, was added ZnCl_2 (81.0 mg, 594 μmol , 1.47 equiv.). After 30 min. NaBH_4 (29.5 mg, 780 μmol , 1.9 equiv.) was added and the mixture was stirred for additional 30 min. Then, 5 mL H_2O was added at $-78\text{ }^{\circ}\text{C}$ and the reaction was left to reach rt. The water phase was extracted with CH_2Cl_2 ($3 \times 10\text{ mL}$). The organic phase was dried over MgSO_4 , filtered, and evaporated under reduced pressure. The crude material was purified on a silica gel column (EtOAc/Hexanes 3:7) and the pure compound **7** was isolated (95.0 mg, 254 μmol , 63 %).

Method B : To 13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one **6** (55 mg, 148 μmol) in 2 mL dry MeOH at $-78\text{ }^{\circ}\text{C}$ was added ZnCl_2 (29.7 mg, 217.8 μmol). After 30 min. NaBH_4 (10.8 mg, 285.5 μmol , 1.47 equiv.) was added and the mixture was stirred for additional 30 min. Then, H_2O (1 mL) was added at $-78\text{ }^{\circ}\text{C}$ and the reaction was left to reach rt. The water phase was extracted 3 times with CH_2Cl_2 . The organic solvent was dried over MgSO_4 , filtered, and evaporated under reduced pressure. The crude material **7** (44 mg, crude yield : 80 %) was directly used in the followed step.

$[\alpha]_D^{24} = +7.0$ (c 0.50, CHCl_3).



$R_f = 0.10$ (EtOAc/Hexanes 3:7).

HRMS-ESI (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{44}\text{NO}$: 374.3417; found 374.3413.


IR (Golden Gate): 2926 (s), 2851 (m), 1703 (m), 1371 (m), 1287 (m).

^1H NMR (300 MHz, CDCl_3) : $\delta = 7.30 - 7.23$ (m, 4H), 7.22 - 7.13 (m, 1H), 3.52 - 3.41 (m, 1H), 2.53 (q, $J = 6.5\text{ Hz}$, 1H), 1.92 (d, $J = 3.4\text{ Hz}$, 1H), 1.55 - 1.48 (m, 1H), 1.47 - 1.39 (m, 1H), 1.38 - 1.30 (m, 4H), 1.26 - 1.01 (m, 22H), 0.81 (d, $J = 6.6\text{ Hz}$, 6H).

^{13}C NMR (101 MHz, CDCl_3) : $\delta = 144.35, 128.47, 127.20, 126.64, 99.99, 69.36, 68.34, 42.17, 39.10, 34.71, 29.99, 29.77, 29.72, 29.63, 29.57, 28.01, 27.47, 25.27, 23.15, 22.72$.



(2*S*,3*R*)-15-methyl-2-(((*R*)-1-phenylethyl)amino)hexadecane-1,3-diol (8)



Method A : To (*R*)-13-methyl-1-((*S*)-1-((*R*)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol **7** (82.2 mg, 220 μ mol) in 2 mL of CH_2Cl_2 was added acetic acid (66.0 μ L, 1.10 mmol, 5 equiv.) and the reaction was stirred for 18 h. Then 1 mL of NaHCO_3 (sat.) was added and the solution was extracted with CH_2Cl_2 (4×10 mL). The organic phase was dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. The crude material was purified over a short silica gel column (EtOAc) to give pure compound **8** (28.3 mg, 72.2 μ mol, 33 %).

Method B : To (*R*)-13-methyl-1-((*S*)-1-((*R*)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol **7** (25 mg, 66 μ mol) in 0.8 mL of CH_2Cl_2 was added acetic acid (20.0 μ L, 0.33 mmol, 5 equiv.) and the reaction was stirred for 2 days. Then 16 μ L of acetic acid were added and the mixture was stirred for 2 h. Then 5 mL of NaHCO_3 (sat.) was added and the solution was extracted with CH_2Cl_2 (3×10 mL) and brine (3×10 mL). The organic phase was dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. The crude product (clear oil, colorless) was purified over a short silica gel column (EtOAc), dissolved in 5 mL of CH_2Cl_2 and 20 μ L of acetic acid were added. After 18 h, the reaction was quenched with 1 mL of NaHCO_3 and the solution was extracted with CH_2Cl_2 (3×10 mL). The organic phase was dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. Then, the product was dissolved in 0.5 mL of EtOH and 4.2 mg (75 mmol) of KOH were added. After stirring for 1.5 h the solvent was evaporated under reduced pressure. After the addition of H_2O , the solution was extracted with CH_2Cl_2 (3×10 mL), the organic phase was dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. A short silica gel column (EtOAc) afforded compound **8** (19 mg, 50 μ mol) in 74 % yield.

$[\alpha]_D^{24} = +21.5$ (c 1.00, CHCl_3).

$R_f = 0.19$ (EtOAc).


HRMS-ESI (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{46}\text{NO}_2$: 392.3523; found 392.3526.

IR (Golden Gate): 3349 (br), 2923 (s), 2852 (m), 1466 (m), 1366 (s), 1065 (m).

^1H NMR (400 MHz, CDCl_3) : $\delta = 7.36$ (dd, $J = 10.2, 2.8$ Hz, 4H), 7.33 – 7.19 (m, 1H), 3.96 (q, $J = 6.5$ Hz, 1H), 3.76 (d, $J = 4.1$ Hz, 2H), 3.63 – 3.52 (m, 1H), 2.49 (dd, $J = 8.0, 4.0$ Hz, 2H), 1.62 – 1.52 (m, 1H), 1.48 – 1.40 (m, 6H), 1.35 – 1.18 (m, 20H), 0.91 (d, $J = 6.6$ Hz, 6H).

^{13}C NMR (101 MHz, CDCl_3) : $\delta = 145.64, 128.59, 127.18, 126.62, 73.59, 60.28, 58.92, 55.94, 39.10, 33.80, 29.99, 29.77, 29.72, 29.69, 29.63, 29.59, 29.56, 28.01, 27.47, 26.12, 24.60, 22.71$.

(2*S*,3*R*)-2-amino-15-methylhexadecane-1,3-diol (**9**)



Method A : To (2*S*,3*R*)-15-methyl-2-(((*R*)-1-phenylethyl)amino)hexadecane-1,3-diol **8** (28.3 mg, 72 μ mol) in 5 mL MeOH was added Pd(OH)₂/C (5 mg) and the mixture was stirred under 1 atm. of H₂ for 48 h. Then the mixture was filtered and the solvents were evaporated under reduced pressure. The crude material was purified on a silica gel column (CH₂Cl₂/MeOH/NH₄OH 0.875:0.11:0.015) to give compound **9** (4.20 mg, 14.6 μ mol) in 20 % yield.

Method B : To (2*S*,3*R*)-15-methyl-2-(((*R*)-1-phenylethyl)amino)hexadecane-1,3-diol **8** (27 mg, 48 μ mol) in 5 mL MeOH was added Pd/C (10 mg) and the mixture was stirred under 1 atm. of H₂ overnight. Then the mixture was filtered over celite and the solvent was evaporated under reduced pressure to afford to the compound **9** (8 mg, 27.8 μ mol) in 58 % yield.

$[\alpha]_D^{22} = -4.4$ (c 0.33, CHCl₃).


$R_f = 0.27$ (CH₂Cl₂/MeOH/NH₄OH 0.875:0.11:0.015).

HRMS-ESI (m/z) : [M+H]⁺ calcd for C₁₇H₃₈NO₂: 288.2897; found 288.2892.


IR (Golden Gate) : 3339 (br), 2922 (s), 2852 (m), 1467 (m), 1384 (w), 1366 (w), 1215 (w), 1051 (w).

¹H NMR (500 MHz, CDCl₃) : $\delta = 3.73 - 3.67$ (m, 2H), 3.66 - 3.58 (m, 1H), 2.88 (br, OH, OH, NH₂, 4H), 2.81 - 2.80 (m, 1H), 1.55 - 1.45 (m, 4H), 1.30 - 1.26 (m, 17H), 1.15 (dt, $J = 7.3, 6.5$ Hz, 2H), 0.86 (d, $J = 6.6$ Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) : $\delta = 74.48, 63.34, 55.77, 39.08, 33.84, 29.97, 29.76, 29.74, 29.72, 29.71, 29.68, 27.98, 27.44, 26.14, 22.67$.



University of Fribourg, Switzerland
 Department of Chemistry / NMR Service
 NMR spectrometer: Bruker Avance III 500 MHz
 Sample: ZUM275 / Solvent: CDCl3(TMS) / TE=298.0 K



2D COSY (500.13 MHz)

```
Current Data Parameters
NAME      zum6107
EXPNO    4
PROCNO   1

F2 - Acquisition Parameters
Date_    20160310
Time     23.30
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  cosygpppf
TD        4096
SOLVENT  CDCl3
NS        32
DS        8
SWH       2200.704 Hz
FIDRES    0.5372011 Hz
AQ        0.0306612 sec
RG        66.06
DW        227.200 usec
DE        6.50 usec
TE        298.2 K
D0        0.0000300 sec
D1        1.2000000 sec
D11       0.0300000 sec
D12       0.0002000 sec
D13       0.0000400 sec
D16       0.0002000 sec
IN0       0.00045440 sec

===== CHANNEL f1 =====
NUC1     1H
P0       11.30 usec
P1       11.30 usec
P17      2500.00 usec
PLW1     16.0000000 W
PLW10    3.0222011 W
SFO1     500.1309080 MHz


===== GRADIENT CHANNEL =====
GPNAM1   SMSG10.100
GPZ1     10.00 %
P16      1000.00 usec

F1 - Acquisition parameters
TD        512
SFO1     500.1309 MHz
FIDRES    4.298250 Hz
SW        4.450 ppm
FnMODE    QF

F2 - Processing parameters
SI        2048
SF        500.130061 MHz
WDW       SINE
SSB       0
LB        0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        512
MC2       QF
SF        500.130066 MHz
WDW       States
SSB       0
LB        0 Hz
GB        0
```

University of Fribourg, Switzerland
 Department of Chemistry / NMR Service
 NMR spectrometer: Bruker Avance III 500 MHz
 Sample: ZUM275 / Solvent: CDCl3(TMS) / TE=298.0 K



2D HMQC

```
Current Data Parameters
NAME      zum6107
EXPNO    5
PROCNO   1

F2 - Acquisition Parameters
Date_    20160311
Time     15.56
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  hmqcgpff
TD        2848
SOLVENT  CDCl3
NS        64
DS        16
SWH       2200.704 Hz
FIDRES    1.074563 Hz
AQ        0.4653558 sec
RG        194.97
DW        227.200 usec
DE        6.50 usec
TE        298.3 K
CNST2    145.0000000
D0        0.0000300 sec
D1        1.0000000 sec
D2        0.0034628 sec
D12       0.0002000 sec
D13       0.0000400 sec
D16       0.0002000 sec
IN0       0.00045440 sec

===== CHANNEL f1 =====
NUC1     1H
P1       11.30 usec
P2       22.60 usec
PLW1     16.0000000 W
PLW2     38.0000000 W
SFO1     500.1309080 MHz

===== CHANNEL f2 =====
CPDPRG2  grrp
NUC2     13C
P3       9.60 usec
PCPD2    70.00 usec
PLW2     98.0000000 W
PLW12    1.8431929 W
SFO2     125.7625000 MHz


===== GRADIENT CHANNEL =====
GPNAM1   SMSG10.100
GPNAM2   SMSG10.100
GPNAM3   SMSG10.100
GPZ1     50.00 %
GPZ2     30.00 %
GPZ3     40.10 %
P16      1000.00 usec

F1 - Acquisition parameters
TD        256
SFO1     125.7625 MHz
FIDRES    43.989304 Hz
SW        85.544 ppm
FnMODE    QF


F2 - Processing parameters
SI        2048
SF        500.130050 MHz
WDW       SINE
SSB       0
LB        0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        512
MC2       QF
SF        125.757704 MHz
WDW       States
SSB       0
LB        0 Hz
GB        0
```

13C{1H} NMR (125.76 MHz), Inverse gated decoupling (d1=20.0 sec.)



(2S,3R)-2-amino-15-methylhexadecan-3-ol (10)



Method A : To (*R*)-13-methyl-1-((*S*)-1-((*R*)-1-phenylethyl)aziridin-2-yl) tetradecan-1-ol **7** (25 mg, 150 μ mol) in 1.8 mL MeOH was added Pd/C (1.3 mg) and the mixture was stirred under 1 atm. of H₂ for 48 h. Then the mixture was filtered and the solvent was evaporated under reduced pressure. The crude material was purified on a silica gel column (CH₂Cl₂/MeOH/NH₄OH 0.875:0.11:0.015) to give compound **9** (3 mg, 11 μ mol, 8 %).

Method B : To (*R*)-13-methyl-1-((*S*)-1-((*R*)-1-phenylethyl)aziridin-2-yl) tetradecan-1-ol **7** (65.9 mg, 176 μ mol) in 5 mL MeOH was added Pd(OH)₂/C (7 mg.) and the mixture was stirred under 1 atm. of H₂ for 48 h. Then the mixture was filtered and the solvents were evaporated under reduced pressure. The crude material was purified on a silica gel column (CH₂Cl₂/MeOH/NH₄OH 0.875:0.11:0.015) to give compound **10** (20.2 mg, 74.4 μ mol, 42 %).

$[\alpha]_D^{24} = + 8.6$ (c 1.00, CHCl₃).



$n_D^{20} = 1.45$ (CH₂Cl₂/MeOH/NH₄OH 0.875:0.11:0.015).

HRMS-ESI (m/z): [M+H]⁺ calcd for C₁₇H₃₈NO: 272.2947; found 272.2950.

IR (Golden Gate): 2915 (s), 2850 (s), 1587 (m), 1468 (m), 1366 (m), 1093 (m).


¹H NMR (400 MHz, CDCl₃) δ 3.49 (dt, *J* = 4.2, 3.8 Hz, 1H), 3.01 (dq, *J* = 6.2, 3.3, 3.2 Hz, 1H), 2.25 (br, OH/NH₂, 3H), 1.55 – 1.47 (m, 2H), 1.44 – 1.35 (m, 2H), 1.30 – 1.26 (m, 17H), 1.17 – 1.13 (m, 2H), 1.04 (d, *J* = 6.6 Hz, 3H), 0.86 (d, *J* = 6.6 Hz, 6H).

^{13}C NMR (125.76 MHz, CDCl_3) δ 74.33, 50.49, 39.07, 32.50, 29.96, 29.78, 29.74, 29.67, 29.69, 29.64, 29.63, 27, 98, 27.43, 26.21, 22.67, 16.37.



University of Fribourg, Switzerland
 Department of Chemistry / NMR Service
 NMR spectrometer: Bruker Avance III 500 MHz
 Sample: ZUM276 / Solvent: CDCl3(TMS) / TE=298.0 K

DEPT135



2D HMQC



Current Data Parameters
 NAME zumb6108
 EXPNO 5
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20160312
 Time 17.06
 INSTRUM spect
 PROBHD 5 mm PABBO BB
 PULPROG hmcpqpf
 TD 2048
 SOLVENT CDCl3
 NS 200
 DS 16
 SWH 2295.794 Hz
 FIDRES 1.074583 Hz
 AQ 0.4603256 sec
 RG 194.07
 DW 227.200 usec
 DE 6.50 usec
 TE 298.2 K
 CNST2 145.000000
 D0 0.0000000 sec
 D1 1.0000000 sec
 D2 0.00344228 sec
 D12 0.0000200 sec
 D13 0.0000400 sec
 D16 0.0002000 sec
 INO 0.0000446 sec
 ===== CHANNEL f1 =====
 NUC1 1H
 P1 11.30 usec
 P2 22.50 usec
 PLW1 16.0000000 W
 SFO1 500.1309800 MHz
 ===== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 13C
 P3 9.60 usec
 PCPD2 70.00 usec
 PLW2 98.0000000 W
 PLW12 1.84319987 W
 SFO2 125.7620000 MHz
 ===== GRADIENT CHANNEL =====
 GPNAM1 SMS216 100
 GPNAM2 SMS216 100
 GPNAM3 SMS216 100
 GP1 50.00 %
 GP2 30.00 %
 GP3 40.10 %
 P16 1060.00 usec
 F1 - Acquisition parameters
 TD 2048
 SF1 125.762 MHz
 FIDRES 43.88304 Hz
 SW 89.984 ppm
 FMODE 0
 F2 - Processing parameters
 SI 2048
 SF 500.130981 MHz
 WDW SINE
 SSB 0
 LB 0 Hz
 GB 0
 PC 1.40
 F1 - Processing parameters
 SI 512
 MC2 512
 SF 125.7577804 MHz
 WDW Sines
 SSB 0
 LB 0 Hz
 GB 0

13C{1H} NMR (125.76 MHz), Inverse gated decoupling (d1=20.0 sec.)



University of Fribourg, Switzerland
 Department of Chemistry / NMR Service
 NMR spectrometer: Bruker Avance III 500 MHz
 Sample: ZUM276 / Solvent: CDCl3(TMS) / TE=298.0 K


Current Data Parameters
 NAME zumb6108
 EXPNO 2
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20160311
 Time 23.38
 INSTRUM spect
 PROBHD 5 mm PABBO BB
 PULPROG zgpg
 TD 65536
 SOLVENT CDCl3
 NS 1024
 DS 0
 SWH 28846.154 Hz
 FIDRES 0.440157 Hz
 AQ 1.1300073 sec
 RG 194.07
 DW 17.333 usec
 DE 6.50 usec
 TE 298.2 K
 D1 20.0000000 sec
 D11 0.0300000 sec
 ===== CHANNEL f1 =====
 NUC1 13C
 P1 9.60 usec
 PLW1 90.0000000 W
 SFO1 125.7709935 MHz
 ===== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 80.00 usec
 PLW2 16.0000000 W
 PLW12 0.34222001 W
 SFO2 500.1320005 MHz
 F2 - Processing parameters
 SI 121072
 SF 125.7577886 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.00



Supplementary Figures:


Supplementary Figure 1.

Labelling of *C. elegans* sphingoid bases using amino acids. **(a)** C17 sphingoid bases detected in animals fed with bacterial diets containing heavy amino acids leucine, isoleucine, valine or lysine, the light and the ^{13}C -containing +4 and +5 isotopic peaks are shown; **(b)** relative amounts of +5 isotopic peak with ^{13}C label incorporation compared to light C17 sphingoid base without isotopic correction; **(c)** scheme of label incorporation from heavy isotope labelled amino acids via branched chain fatty acids into sphingoid bases.



Supplementary Figure 2.

Calculation of width of GFP positive intestinal lumen and width of F-actin signal visualized by SiR-actin. (a-b) representative line profile of fluorescent signals from OP50 GFP in the intestinal lumen (cyan line, a) and SiR-actin (magenta line, b) and their Gaussian fits (dashed lines) recorded perpendicular to the intestinal lumen in animals treated with ethanol vehicle; (c-e) average Gaussian fits of GFP signals (cyan) and SiR-actin (magenta) for animals treated with solvent control EtOH (c), C17 iso-branched sphinganine, id17:0 (d) and 1-deoxy C17 iso-branched sphinganine, im17:0 (e); (f) width of the intestinal lumen as given by the full width at half maximum of a single Gaussian fit of the GFP signal; (g) width of the apical F-actin signal as calculated by the width of two Gaussian fits of the SiR-actin signal, statistical significance determined by Welch's t-test * $p < 0.05$, *** $p < 0.005$.



Supplementary Figure 3.

Saturated image of Figure 5 to better visualize growth of *lcb1Δ* strain on racemic C16 DL-sphinganine (DL-d16:0).

